Skip to main content
TipRanks
Go Ultimate75% OFF

Evommune, Inc. (EVMN) Stock Price & Analysis

141 Followers

EVMN Stock Chart & Stats

$7.02-$0.08(-1.13%)
At close: 4:00 PM EST
$5$10$15Aug 24Sep 8Sep 21Oct 5Oct 19Nov 2Nov 16
Day’s Range
$6.77 - $7.19
52-Week Range
$4.94 - $33.20
Previous Close
$7.10
Volume
N/A
Average Volume (3M)
919.86K
Market Cap
$290.28M
Enterprise Value
$139.61M
Total Cash (Recent Filing)
$168.64M
Total Debt (Recent Filing)
$8.19M
Price to Earnings (P/E)
―
Beta
0.79
Next Earnings
Mar 11, 2027 (Est.)
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Strengthened Balance Sheet

Very low leverage gives Evommune greater financial flexibility while it advances clinical programs. The strengthened capital structure can reduce near-term balance-sheet pressure and provide more capacity to absorb development setbacks or fund prioritized trials.

Promising EVO301 Clinical Signal

EVO301 has produced a meaningful controlled efficacy signal in atopic dermatitis, supported by favorable tolerability and biomarker evidence. Quarterly dosing potential and broad pathway activity could improve the asset's differentiation if confirmed in Phase 2b.

Expanding Immunology Pipeline

The combination of biologic and small-molecule programs across inflammatory and autoimmune diseases diversifies clinical catalysts beyond one asset. EVO570 also broadens the target biology and potential disease reach of Evommune's development platform.

Bears Say

No Current Revenue Base

Evommune currently lacks recurring operating revenue to offset research and development spending. This leaves financial progress dependent on clinical success, licensing activity, or external capital rather than an established commercial engine, increasing execution sensitivity.

Heavy Ongoing Cash Burn

Persistent negative operating and free cash flow means the company consumes substantial capital while its programs remain in development. Continued investment will likely require disciplined prioritization and may create future financing needs before products generate revenue.

EVO756 Atopic Dermatitis Failure

The failed Phase 2b study removes an indication from EVO756's development opportunity and shifts greater strategic importance to EVO301. It also demonstrates that the broader pipeline remains exposed to meaningful clinical and program-level execution risk.

Evommune, Inc. News

EVMN FAQ

What was Evommune, Inc.’s price range in the past 12 months?
Evommune, Inc. lowest stock price was $4.94 and its highest was $33.20 in the past 12 months.
What is Evommune, Inc.’s market cap?
Evommune, Inc.’s market cap is $290.28M.
When is Evommune, Inc.’s upcoming earnings report date?
Evommune, Inc.’s next earnings report is estimated for Mar 11, 2027 (not yet confirmed), which is in 113 days.
How were Evommune, Inc.’s earnings last quarter?
Evommune, Inc. released its earnings results on Nov 12, 2026. The company reported -$0.85 earnings per share for the quarter, missing the consensus estimate of -$0.834 by -$0.016.
Is Evommune, Inc. overvalued?
According to Wall Street analysts Evommune, Inc.’s price is currently Undervalued.
Does Evommune, Inc. pay dividends?
Evommune, Inc. does not currently pay dividends.
What is Evommune, Inc.’s EPS estimate?
Evommune, Inc.’s EPS estimate is -1.00.
How many shares outstanding does Evommune, Inc. have?
Evommune, Inc. has 41,349,860 shares outstanding.
What happened to Evommune, Inc.’s price movement after its last earnings report?
Evommune, Inc. reported an EPS of -$0.85 in its last earnings report, missing expectations of -$0.834. Following the earnings report the stock price went down -4.863%.
Which hedge fund is a major shareholder of Evommune, Inc.?
Hedge funds hold Evommune, Inc. shares: the largest hedge-fund position in Evommune, Inc. is 72,418,464 shares, and hedge funds decreased their holdings by 235.4K shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology